INTRODUCTION

Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) and bladder outlet obstruction in elderly men. It is generally accepted that surgery is the standard of care for most cases of symptomatic BPH after failure of medical therapy. Holmium laser enucleation of the prostate (HoLEP) is a well-established, minimally invasive treatment for BPH.

Purpose:

To identify the clinical and pathological characteristics of hard nodules resistant to morcellation (HNRM) during holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH).

Methods:

Between July 2008 and October 2011, 246 patients underwent HoLEP for symptomatic BPH. The first 30 patients were excluded from the analysis due to the learning curve of the procedure. The remaining patients were divided into HNRM (n = 29) and non-HNRM groups (n = 187), and comparative analysis of the clinical parameters of the two groups was performed. International prostate symptom score analysis and urodynamic studies were performed preoperatively. Histological analysis was performed after hematoxylin and eosin staining and Masson trichrome staining of the HNRM specimens.

Results:

Twenty-nine patients (13.4%) had HNRM. The patients in the HNRM group had significantly higher proportions of advanced age (≥ 65 years, P = 0.029), total prostate volume ≥ 65 mL (P < 0.001), transition zone volume ≥ 35 mL (P < 0.001), serum prostate-specific antigen levels ≥ 10 ng/mL (P = 0.007), and functional urethral length ≥ 70 mm (P = 0.009); larger enucleation weight (P < 0.001); longer operation (P = 0.001), enucleation (P = 0.042), and morcellation times (P < 0.001); and higher enucleation ratio (P = 0.028) and enucleation efficacy (P = 0.001). After adjusting for confounding factors, multivariate logistic regression analysis revealed that age ≥ 65 years and total prostate volume ≥ 65 mL were independent risk factors for HNRM. Pathological examination did not reveal any malignant cells, with mainly dense fibrous tissue found in the HNRM.

Conclusions:

HNRM can make morcellation cumbersome and time-consuming, and older patients with larger prostates have a higher incidence of HNRM. However, the histopathology of HNRM revealed mainly fibrotic tissue.

Keywords: Laser Therapy; Prostate; Prostatic Hyperplasia; Transurethral Resection of Prostate

Original Article

Int Neurourol J 2015;19:90-98
http://dx.doi.org/10.5213/inj.2015.19.2.90
pISSN 2093-4777 · eISSN 2093-6931
ment option for men with BPH [1]. There is an increasing amount of evidence supporting the safety and efficacy of HoLEP for BPH when compared to other surgical treatments such as open prostatectomy and transurethral resection of the prostate [2,3]. However, a number of studies have shown that a steep learning curve exists for this operation, thus limiting its widespread use.

In most cases, morcellation can be efficiently and safely performed in patients with prostate of varying sizes [4]. In recent years, this procedure has been improved significantly by the application of mechanical tissue morcellators [5,6]. However, notably, previous studies have reported that the so-called “crazy ball” or “beach ball” effect, which is caused by tissue spheres against the blade of the morcellator, makes morcellation difficult [7,8]. Additionally, El-Hakim and Elhilali [9] reported that small round tissue fragments may persist after morcellation and that these “beach balls” are difficult to morcellate because they dislodge from the morcellator blades. These findings are consistent with our clinical experience.

In the present study, the tissue mentioned above is referred to as hard nodules resistant to morcellation (HNRM). Although previous investigations have shown the existence of HNRM and pointed out that this phenomenon can be cumbersome during morcellation, their impact on the operation efficiency remains unknown, as do their clinical parameters and pathological characteristics. Therefore, this study aimed to identify the clinical and pathological characteristics associated with HNRM.

**MATERIALS AND METHODS**

**Study Population**

This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1111-040-385). A total of 216 consecutive patients who underwent HoLEP for symptomatic BPH between July 2008 and October 2011 were included. Patients with a history of genitourinary malignancy, genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were excluded from the study. Additionally, patients with a history of genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were excluded from the study. Additionally, patients with a history of genitourinary malignancy, genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were included. Patients with a history of genitourinary malignancy, genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were included. Patients with a history of genitourinary malignancy, genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were included. Patients with a history of genitourinary malignancy, genitourinary surgery or radiation, interstitial cystitis or bladder pain syndrome, urinary tract infection, or congenital genitourinary anomaly were included.

**Operative Procedure**

All surgical procedures were performed by one surgeon (S.J.O.) according to the technique described previously [10]. In brief, anatomical enucleation was adopted using the three-lobe technique. A 26-Fr resectoscope (Karl Storz, Tuttingen, Germany) was used for enucleation of the prostate. A 550-μm end-firing laser fiber (SlimLine, Lumenis Ltd., Yokneam, Israel) was engaged with an 80-W holmium neodymium:yttrium-aluminum-garnet laser (VersaPulse Power-Suite, Lumenis Ltd.). The energy power was usually set at 2 J and 40 Hz. Continuous irrigation was applied with normal saline during enucleation and morcellation. The mechanical morcellator used was a VersaCut morcellator (Lumenis Ltd.) through a 0-degree rectangular nephroscope (Karl Storz). If the lump was small, it was washed out through the resectoscope sheath naturally. After complete retrieval of the enucleated prostatic tissue from the bladder, usually a 22-Fr 3-way urethral catheter was inserted for continuous bladder irrigation with normal saline. At the end of the operation, the extracted tissues were weighed after removing the irrigation fluid and sent for pathological analysis.

**Definition of HNRM**

HNRM was defined as an enucleated prostate lump that was resistant to morcellation and required alternative methods for extracting the tissue from the bladder. The time needed for the alternative method was included in the morcellation time. Some nodules were retrieved using special equipment such as an endoscopic grasper. In some cases, the HNRM were lodged in the morcellator blades and caused morcellator failure. In those cases, electronic transurethral resection was adopted for further fragmentation of the enucleated HNRM. Commonly, the morcellator blades were replaced after eight surgeries.

**Clinical Data Collection and Definition of Variables**

All patients were evaluated preoperatively by physical examination with digital rectal examination, scoring of subjective symptoms with the International Prostate Symptom Score (IPSS), quality of life (QoL) assessment, laboratory analysis with urinalysis, urine culture (in the presence of pyuria), total serum prostate-specific antigen (PSA), and transrectal prostate ultrasound. Multichannel video urodynamic study (MMS UD 2000, Medical Measurement System, Enschede, The Netherlands) was performed to help identify obstruction and overactivity of the bladder components of the LUTS if necessary. To facilitate the statistical analysis, age (<65 years vs. ≥65 years), body

---

**Inj Neurourol J 2015;19:90-98**

**www.einj.org**

---

Piao, et al.  •  Hard Nodules Resistant to Morcellation
mass index (<23 vs. kg/m^2 ≥23 kg/m^2), subtotal voiding symptom score (<5 vs. ≥5), subtotal storage symptom score (<4 vs. ≥4), total prostate volume (TPV; <65 mL vs. ≥65 mL), transition zone volume (<35 mL vs. ≥35 mL), PSA (<10 ng/mL vs. ≥10 ng/mL), and functional urethral length (<70 mm vs. ≥70 mm) were dichotomized. The bladder outlet obstruction index, which is equal to the detrusor pressure at the maximal flow rate (PdetQmax)–2Qmax, was used to evaluate the bladder outlet obstruction [11]. According to the bladder contractility index, bladder contractility can be determined as strong (>150), normal (100–150), and weak (<100) [12]. The IPSS scores were defined as no or mild (0–7) and moderate or severe (≥8), and the QoL scores were defined as mild (0–1) or moderate or severe (≥2) [13]. Operative parameters were obtained from the operation records, and included the retrieved tissue weight, operative time, enucleation time, morcellation time, enucleation ratio (enucleated weight/transition zone volume), enucleation efficacy (enucleated weight/enucleation time), morcellation efficacy (enucleated weight/morcellation time), enucleation ratio efficacy (enucleation ratio/enucleation time) [14], intraoperative complications, and perioperative outcomes. Complications were assessed according to the Clavien-Dindo classification [15].

**Histological Evaluation**

The tissue slices from the prostatectomy specimens were fixed in 10% phosphate buffered formalin, embedded in paraffin, and sectioned and stained with hematoxylin and eosin. Masson trichrome staining was carried out for the HNRM group to distinguish the prostate smooth muscle cells (red) from collagen fibers (blue) and other stromal cell types. Sections were imaged using microscopy (Leica Microsystems, Wetzlar, Germany) at magnifications of ×100 and ×200.

**Statistical Methods**

The independent t-test or Mann-Whitney U-test was used for comparing the mean differences in continuous variables between the two groups. Pearson chi-square or Fisher exact test was used for binary variables. To identify the independent risk factors for HNRM, we performed univariate and multivariate analyses with logistic regression to estimate the strength of influence of each variable. The odds ratios and 95% confidence intervals were calculated. All P-values were two-sided, and P<0.05 was considered statistically significant. Data were analyzed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA).

**RESULTS**

**Baseline Characteristics and Clinical Parameters**

Twenty-nine patients (13.4%) were found to have HNRM during morcellation. The basic demographics of the study patients are listed in Table 1. The HNRM group had significantly higher proportions of older age (≥65 years), larger total volume (≥65 mL) and transition zone volume (≥35 mL) of the prostate, higher serum PSA levels (≥10 ng/mL), and longer functional urethral length (≥70 mm) than the non-HNRM group (P<0.05). In addition, the former group had significantly longer operation, enucleation, and morcellation times; larger enucleation weight; higher enucleation ratio and enucleation efficacy; and more energy consumption than the latter (P<0.05). There were no significant differences in the other urodynamic variables (P>0.05). Intraoperative complications occurred in 25 cases, including 5 case of bladder mucosal injury (Clavien-Dindo classification grade I) and 6 cases of prostatic capsular injury (grade I). The complication rates were similar between the two groups (P>0.05). All complications were mild and were managed properly. Additionally, there were no significant differences in the length of hospital stay between the two groups (P>0.05) or in the operative efficiency, including the morcellation efficacy and enucleation ratio efficacy (P>0.05).

The risk factors for HNRM are shown in Table 2. In the univariate logistic regression models, age ≥65 years, PSA ≥10 ng/mL, TPV ≥65 mL, transition zone volume ≥35 mL, and functional urethral length ≥70 mm were significant risk factors. In the multivariate logistic regression model, age ≥65 years and TPV ≥65 mL were found to be significantly and independently associated with HNRM. Presence of longer functional urethral length ≥70 mm was a borderline significant risk factor in multivariate regression analysis.

**Histological Analysis**

The shapes of the HNRM were irregular, with diameters ranging from 7 to 13 mm, as shown in Fig. 1. Each HNRM was grayish-white with a tough consistency. Microscopically, hematoxylin and eosin staining showed that most nodules were predominantly fibrous proliferations, with only scattered blood vessels and occasional inflammatory cells noted. No malignant cells were observed, and the glandular cells were found to have uniform and basally located, small nuclei. The stromal tissues...
### Table 1. Baseline characteristics of the study patients

| Variable                                      | All patients (n = 216) | Non-HNRM (n = 187) | HNRM (n = 29) | P-value |
|-----------------------------------------------|------------------------|--------------------|---------------|---------|
| Age (yr)                                      | 69.1 ± 6.7             | 68.7 ± 6.7         | 71.1 ± 6.6    | 0.079   |
| < 65                                          | 49 (22.7)              | 47 (25.1)          | 2 (6.9)       |         |
| ≥ 65                                          | 167 (77.3)             | 140 (74.9)         | 27 (93.1)     |         |
| Body mass index (kg/m²)                       | 23.8 ± 3.0             | 23.8 ± 3.0         | 24.4 ± 2.7    | 0.309   |
| < 23                                          | 85 (39.4)              | 78 (41.7)          | 7 (24.1)      |         |
| ≥ 23                                          | 131 (60.6)             | 109 (58.3)         | 22 (75.9)     |         |
| Past medical history                          |                        |                    |               |         |
| Hypertension                                  | 100 (45.0)             | 84 (44.9)          | 16 (55.2)     | 0.303   |
| Diabetes mellitus                             | 40 (18.0)              | 35 (18.7)          | 5 (17.2)      | 0.849   |
| Cardiovascular disease                        | 12 (5.6)               | 12 (6.4)           | 0 (0)         | 0.160   |
| Neurologic disease                            | 24 (11.1)              | 18 (9.6)           | 6 (20.7)      | 0.148   |
| Alpha-blocker                                  | 153 (70.8)             | 132 (70.6)         | 21 (72.4)     | 0.841   |
| 5-Alpha-reductase inhibitor                    | 50 (23.1)              | 44 (23.5)          | 6 (20.7)      | 0.736   |
| Anticholinergics                              | 11 (5.1)               | 10 (5.3)           | 1 (3.4)       | 1.000   |
| IPSS                                          |                        |                    |               |         |
| Subtotal voiding symptom score                | 10.3 ± 5.4             | 10.3 ± 5.4         | 10.9 ± 5.1    | 0.601   |
| < 5                                           | 22 (12.4)              | 20 (13.1)          | 2 (8.3)       |         |
| ≥ 5                                           | 155 (87.6)             | 133 (86.9)         | 22 (91.7)     | 0.748   |
| Subtotal storage symptom score                | 7.1 ± 3.7              | 7.1 ± 3.6          | 7.7 ± 4.0     | 0.444   |
| < 4                                           | 29 (16.4)              | 26 (17.0)          | 3 (12.5)      |         |
| ≥ 4                                           | 148 (83.6)             | 127 (83.0)         | 21 (87.5)     | 0.798   |
| Total IPSS                                    | 17.5 ± 7.9             | 17.3 ± 7.9         | 18.5 ± 8.0    | 0.478   |
| < 8                                           | 21 (11.9)              | 20 (13.1)          | 1 (4.2)       | 0.360   |
| ≥ 8                                           | 156 (88.1)             | 133 (86.9)         | 23 (95.8)     |         |
| QoL index                                     | 4.1 ± 1.2              | 4.1 ± 1.2          | 4.3 ± 0.9     | 0.525   |
| 0–1                                           | 8 (4.5)                | 8 (3.3)            | 0 (0)         |         |
| ≥ 2                                           | 168 (95.5)             | 144 (95.7)         | 24 (100)      | 0.533   |
| PSA (ng/mL)                                   | 3.8 ± 3.7              | 6.3 ± 5.4          | 4.1 ± 4.0     | 0.001*  |
| < 10                                          | 200 (93.9)             | 176 (95.7)         | 24 (82.8)     |         |
| ≥ 10                                          | 13 (6.1)               | 8 (4.3)            | 5 (17.2)      | 0.007*  |
| Prostate volume (mL)                          |                        |                    |               |         |
| Total prostate volume                         | 67.6 ± 30.3            | 65.3 ± 30.5        | 82.2 ± 24.9   | 0.005*  |
| < 65                                          | 113 (53.1)             | 108 (58.7)         | 5 (17.2)      |         |
| ≥ 65                                          | 100 (46.9)             | 76 (41.3)          | 24 (82.8)     | < 0.001*|
| Transition zone volume                        | 38.6 ± 24.0            | 37.0 ± 24.5        | 48.7 ± 18.1   | 0.014*  |
| < 35                                          | 109 (57.1)             | 104 (57.1)         | 5 (17.2)      |         |
| ≥ 35                                          | 102 (48.3)             | 78 (42.9)          | 24 (82.8)     | < 0.001*|
| Uroflowmetry                                  |                        |                    |               |         |
| Maximum flow rate (mL/s)                      | 1.2 ± 1.3              | 1.2 ± 1.1          | 1.4 ± 1.9     | 0.339   |
| PVR (mL)                                      | 165.3 ± 118.5          | 169.0 ± 121.0      | 138.8 ± 98.5  | 0.228   |
| Urodynamic variable                           |                        |                    |               |         |
| MCC (mL)                                      | 356 ± 117.8            | 360.7 ± 117.4      | 329.1 ± 118.9 | 0.187   |
| Involuntary detrusor contraction              | 109 (52.7)             | 94 (52.5)          | 15 (53.6)     | 0.917   |
| FUL (mm)                                      | 76.1 ± 11.8            | 75.4 ± 11.9        | 80.4 ± 9.8    | 0.034*  |
| < 70                                          | 57 (27.7)              | 55 (30.9)          | 2 (7.1)       |         |
| ≥ 70                                          | 149 (72.3)             | 123 (69.1)         | 26 (92.9)     | 0.009*  |
| MUCP                                          | 74.8 ± 27.7            | 76.2 ± 28.3        | 66.4 ± 21.7   | 0.083   |
| PdetQmax (cm water)                           | 63.5 ± 28.2            | 68.9 ± 29.1        | 68.2 ± 28.2   | 0.898   |

(Continued to the next page)
Table 1. Continued

| Variable                                | All patients (n = 216) | Non-HNRM (n = 187) | HNRM (n = 29) | P-value |
|-----------------------------------------|------------------------|--------------------|--------------|---------|
| Bladder contractility index             |                        |                    |              |         |
| < 100                                   | 109.6 ± 37.0           | 109.8 ± 38.3       | 108.5 ± 27.8 | 0.862   |
| 100–150                                 | 117.7 ± 36.0           | 117.5 ± 36.4       | 116.5 ± 28.8 | 0.185   |
| > 150                                   | 126.7 ± 35.8           | 126.3 ± 35.8       | 125.7 ± 28.8 | 0.001*  |
| Bladder outlet obstruction index        |                        |                    |              |         |
| < 40                                    | 53.2 ± 29.5            | 53.1 ± 30.3        | 53.8 ± 24.1  | 0.957   |
| ≥ 40                                    | 129 (62.6)             | 110 (61.8)         | 19 (67.9)    | 0.538   |
| Intraoperative complications            |                        |                    |              |         |
| Bladder injury                          | 5 (2.3)                | 4 (2.1)            | 1 (3.4)      | 0.663   |
| Prostatic capsular injury               | 6 (2.7)                | 5 (2.7)            | 1 (3.4)      | 0.813   |
| Bleeding                                | 14 (6.5)               | 13 (7.0)           | 1 (3.4)      | 0.476   |
| Perioperative data                      |                        |                    |              |         |
| Operation time (min)                    | 61.7 ± 30.6            | 59.0 ± 28.9        | 79.6 ± 35.5  | 0.001*  |
| Enucleation time (min)                  | 43.8 ± 18.3            | 42.8 ± 18.9        | 50.2 ± 11.8  | 0.042*  |
| Morcellation time (min)                 | 12.5 ± 12.3            | 11.1 ± 10.0        | 21.4 ± 19.9  | <0.001* |
| Enucleation weight (g)                  | 25.6 ± 22.0            | 23.6 ± 21.5        | 38.5 ± 21.4  | <0.001* |
| Enucleation ratio (g/mL)                | 0.6 ± 0.4              | 0.6 ± 0.4          | 0.8 ± 0.3    | 0.028*  |
| Enucleation efficacy (g/min)            | 0.5 ± 0.4              | 0.5 ± 0.4          | 0.7 ± 0.3    | 0.001*  |
| Morcellation efficacy (g/min)           | 2.9 ± 1.4              | 2.9 ± 1.4          | 2.4 ± 1.4    | 0.622   |
| Enucleation ratio efficacy (g/mL/min)   | 0.015 ± 0.011          | 0.015 ± 0.012      | 0.016 ± 0.007| 0.718   |
| Energy (kJ)                             | 91.0 ± 36.3            | 88.6 ± 36.1        | 106.1 ± 33.8 | 0.015*  |
| Incomplete enucleation                  | 2 (0.9)                | 1 (0.5)            | 1 (3.4)      | 0.198   |
| Hospital stay (day)                     | 2.0 ± 1.0              | 2.3 ± 1.0          | 2.5 ± 0.6    | 0.444   |

Values are presented as mean ± standard deviation or number (%).
HNRM, hard nodules resistant to morcellation; IPSS, International Prostate Symptom Score; QoL, quality of life; PSA, prostate-specific antigen; PVR, postvoid residual; MCC, maximum cystometric capacity; FUL, functional urethral length; MUCP, maximum urethral closure pressure; PdetQmax, detrusor pressure at the maximal flow rate.
*P < 0.05, statistically significant difference.

---

Fig. 1. Gross findings of a hard nodule.

around the glandular cells were highly proliferated and exhibited a high density of fibers (Fig. 2A). Little calcification was observed. Masson trichrome staining of the HNRM sections showed that the tissue was predominantly and intensely stained blue, containing very little red staining and a few black-stained nuclei (Fig. 2B).

DISCUSSION

Currently, the etiology of hard nodules of BPH is not fully understood. However, prostate ischemia has been proposed to contribute to prostate fibrosis [16]. Kozlowski et al. [17] reported that chronic ischemia resulted in thickening and fibrosis of the prostate in rats, and, similarly, Zaripour et al. [18] showed that chronic pelvic ischemia caused distinct functional and morphological changes in the prostate in a rat model of arterial endothelial injury, with prostatic tissue from ischemic animals showing an increased deposition of collagen. Moreover, Bauman et al. [19] showed that the proportion of larger bundles of collagen, but not total collagen, was increased in BPH nodules, and concluded that these fibers may play a role in BPH. Berger
et al. [20], using contrast-enhanced color Doppler ultrasonography, found that perfusion in the transition zone of the prostate was significantly reduced in men with diabetes or peripheral arterial occlusive disease, compared to healthy controls. Taken together, this indicates that age-related impairment of blood supply to the lower urinary tract might play a role in the development of BPH and that it may also impact prostate enlargement and/or prostatic smooth muscle tone. In this study, the observed relationship between HNRM and histologic changes in the prostate is difficult to explain, but we speculate that the relation may be due to aging-related chronic ischemia of the lower urinary tract. However, further studies are needed to explore the relationship between fibrotic change and HNRM.

In the present study, clinical parameters were compared between non-HNRM and HNRM groups. Furthermore, the significant predictors related to HNRM were determined, and the histologic features of HNRM were analyzed. The results showed that, compared with patients in the non-HNRM group, the patients in the HNRM group had significantly higher age, larger total and transition zone volumes of the prostate, and higher serum PSA levels, confirming that prostate volume and serum PSA concentration were significantly and positively correlated with advanced age, as previously reported [21].

Our results also indicated that the presence of HNRM could significantly extend the operation, enucleation, and morcellation times. If the core sizes were small, HNRM could be morcellated efficiently or retracted using forceps, whereas if the core sizes were too large to pass through the resectoscope sheath, resection using an electronic resection loop or laser firing for further fragmentation was required in order to allow the HNRM to be extracted through the sheath. As a result, the operation, enucleation, and morcellation times in patients in the HNRM

### Table 2. Univariate and multivariate predictors

| Variable                                      | Univariable | Multivariable |
|-----------------------------------------------|-------------|---------------|
|                                               | P-value     | OR            | 95% CI         | P-value | OR            | 95% CI         |
| Age (yr) ≥ 65 vs. < 65                        | 0.044*      | 4.532         | 1.038–19.787   | 0.021*  | 6.049         | 1.316–27.797   |
| Body mass index (kg/m²) ≥ 23 vs. < 23         | 0.077       | 2.249         | 0.915–5.525    |         |               |                |
| Hypertension                                  | 0.305       | 1.509         | 0.687–3.314    |         |               |                |
| Neurogenic bladder                            | 0.086       | 2.449         | 0.882–6.802    |         |               |                |
| 5-Alpha-reductase inhibitor                    | 0.736       | 0.848         | 0.325–2.214    |         |               |                |
| Total prostate volume (mL) ≥ 65 vs. < 65      | < 0.01*     | 6.821         | 2.491–18.676   | 0.005*  | 4.648         | 1.589–13.595   |
| Transition zone volume (mL) ≥ 35 vs. < 35     | < 0.01*     | 6.4           | 2.337–17.523   |         |               |                |
| Prostate-specific antigen (ng/mL) ≥ 10 vs. < 10| 0.013       | 4.583         | 1.386–15.156   | 0.147   | 2.702         | 0.706–10.336   |
| Maximum flow rate                             | 0.18        | 0.186         | 0.016–2.176    |         |               |                |
| Residual urine volume                         | 0.29        | 0.998         | 0.994–1.002    |         |               |                |
| Maximum cystometric capacity                  | 0.225       | 0.998         | 0.995–1.001    |         |               |                |
| Functional urethral length (mm) ≥ 70 vs. < 70  | 0.019*      | 5.813         | 1.333–25.357   | 0.082   | 3.918         | 0.841–18.259   |
| Bladder contractility index                   | 0.735       | 0.998         | 0.989–1.008    |         |               |                |
| Bladder outlet obstruction index              | 0.947       | 1.000         | 0.987–1.014    |         |               |                |
| Total IPSS ≥ 8 vs. < 8                        | 0.237       | 3.459         | 0.442–27.043   |         |               |                |
| QoL index                                     | 0.523       | 1.134         | 0.771–1.670    |         |               |                |

OR, odds ratio; CI, confidence interval; IPSS, international prostate symptom score; QoL, quality of life.

*P < 0.05, statistically significant difference.
group were significantly longer than in the non-HNRM group. To the best of our knowledge, this is the first study showing HNRM as a hindrance to morcellation, making it cumbersome and time-consuming. Vavassori et al. [7] suggested keeping at least two new, spare sharp blades available in order to avoid the issue of tissue spheres against the sheath of the morcellator; however, it should be noted that the morcellation was not improved by using fresh morcellator blades in the present study. The patients in the HNRM group showed significant higher enucleation ratio and enucleation efficacy than the patients in non-HNRM group. In a previous study, both the enucleation and morcellation efficacy showed a strong linear correlation with prostate size in all patients [10], implying that HoLEP is more effective for larger prostates. However, this clear linear correlation was not observed in this study. Herein, the morcellation efficacy did not show a significant difference between the groups. The morcellation efficacy is mainly limited by the presence of hard nodules, as hard nodules are generally difficult to grasp and cut with the morcellator device, resulting in the morcellation being cumbersome and time-consuming. On the other hand, patients with HNRM had significantly larger prostate volume than those with non-HNRM in the current study. Consequently, the absolute value of the morcellation time in each patient in the HNRM group was significantly longer. Furthermore, there was no significant difference in the morcellation efficacy between the non-HNRM and HNRM groups as a result of the hard nodules. In addition, in the HNRM group, the patients showed a significant longer functional urethral length than those in the non-HNRM group. This result was consistent with the finding that there was a significant increase in the prostate volume in the HNRM group. Lastly, in this study, the preoperative patient data (Table 1) revealed that the score for each IPSS parameter and the urodynamic parameters were not significantly different in patients with or without HNRM. Taken together, these findings confirm the results of previous studies, suggesting that LUTS do not appear to correlate with the prostate size, PSA level [22], or urinary flow rate [23-25].

The most serious potential complication during HoLEP is bladder perforation, which can result from collapse of the bladder dome onto the morcellator as a result of inadequate bladder filling during intravesical tissue morcellation. Extended morcellation time increases this risk; therefore, adequate irrigate inflow should be maintained during morcellation. Further, as expected, complications were rare and no significant difference in the complication rate was observed between the groups in this study (Table 1). However, a larger case series is warranted for further evaluation.

Finally, univariate and multivariate logistic regression models were used to calculate the odds ratios of HNRM for potential risk factors (Table 2). Advanced age, larger total and transition zone volumes, higher PSA levels, and longer functional urethral length were found to be individually associated with outcomes in the univariate logistic regression models. Moreover, in the multivariate regression analysis, advanced age and larger TPV were independent risk factor for HNRM. The trend between advanced age and TPV has been previously demonstrated, and in the current study, presence of HNRM appeared to follow the same trend. Histologically, the HNRM were found to consist of fibrotic tissue, and previous in vivo studies have demonstrated the evolution of stromal fibrosis with progression of BPH [26].

This study has some potential limitations. First, this was a retrospective study and unidentified confounding factors beyond our control may have been present. Furthermore, our study cohort was collected from a single institution with a relatively limited number of patients. Therefore, further studies on the prediction of HNRM before surgery are expected in the near future, for example using computed tomography or transrectal prostatic ultrasound analysis. A more thorough evalu-
tion in a larger series of patients with HNRM is necessary to confirm the results.

In conclusion, our results showed that the presence of HNRM can make morcellation cumbersome and time-consuming. The proportion of HNRM increased in patients with advanced age ≥ 65 years and with a TPV ≥ 65 mL. Moreover, histologically, the HNRM were found to mainly be composed of fibrotic tissue.

REFERENCES

1. Gilling PJ, Cass CB, Cresswell MD, Fraundorfer MR. Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology 1996;47:48-51.
2. Kim M, Lee HE, Oh SJ. Technical aspects of holmium laser enucleation of the prostate for benign prostatic hyperplasia. Korean J Urol 2013;54:570-9.
3. Kuo RL, Paterson RF, Kim SC, Siqueira Jr TM, Elhilali MM, Lingeman JE. Holmium laser enucleation of the prostate (HoLEP): a technical update. World J Surg Oncol 2003;1:6.
4. Hettiarachchi JA, Samadi AA, Konno S, Das AK. Holmium laser enucleation for large (greater than 100 mL) prostate glands. Int J Urol 2002;9:233-6.
5. Fraundorfer MR, Gilling PJ. Holmium-YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol 1998;33:69-72.
6. Elzayat EA, Habib EI, Elhilali MM. Holmium laser enucleation of the prostate: a size-independent new "gold standard". Urology 2005;66(5 Suppl):108-13.
7. Vavassori I, Valenti S, Naspro R, Vismara A, Dell'Acqua V, Manzetti A, et al. Three-year outcome following holmium laser enucleation of the prostate combined with mechanical morcellation in 330 consecutive patients. Eur Urol 2008;53:599-604.
8. Ritter M, Krombach P, Bolenz C, Martinschek A, Bach T, Haeker A. Standardized comparison of prostate morcellators using a new ex-vivo model. J Endourol 2012;26:697-700.
9. El-Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int 2002;90:863-9.
10. Bae J, Oh SJ, Paick JS. The learning curve for holmium laser enucleation of the prostate: a single-center experience. Korean J Urol 2010;51:688-93.
11. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn 1997;16:1-18.
12. Nitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol 2005;7 Suppl 6:S14-21.
13. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57.
14. Jeong CW, Oh JK, Cho MC, Bae JB, Oh SJ. Enucleation ratio efficacy might be a better predictor to assess learning curve of holmium laser enucleation of the prostate. Int Braz J Urol 2012;38:362-71.
15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13.
16. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998;82 Suppl 1:26-33.
17. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001;165:1019-26.
18. Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalaafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate 2015;75:233-41.
19. Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, et al. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One 2014;9:e109102.
20. Berger AP, Horninger W, Bektic J, Pelzer A, Spranger R, Bartsch G, et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int 2006;98:587-90.
21. Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003;37:322-8.
22. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150(2 Pt 1):351-8.
23. Ezz el Din K, Kiemeney LA, de Wilde MJ, Debruyne FM, de la Ro-
sette JJ. Correlation between uroflowmetry, prostate volume, post-void residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996;48:393-7.
24. van Venrooij GE, Boon TA. The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J Urol 1996;155:2014-8.
25. Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001;57:695-700.
26. Rosenzweig-Bublil N, Abramovici A. Stromal fibrosis reaction in rat prostates induced by alpha 1 adrenergic stimulation. J Androl 2006;27:276-84.